Titre :

Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)

Auteur(s) :

Nougier, Christophe [Auteur]
Hospices Civils de Lyon [HCL]
Jeanpierre, Emmanuelle [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Ternisien, Catherine [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Proulle, Valérie [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Hezard, Nathalie [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Pouplard, Claire [Auteur]
Service d'hématologie [Tours]
Lasne, Dominique [Auteur]
Hémostase, Inflammation, Thrombose [HITH - U1176 Inserm - CHU Bicêtre]
Hôpital Necker - Enfants Malades [AP-HP]

Titre de la revue :

European Journal of Haematology

Pagination :

675-681

Éditeur :

Wiley

Date de publication :

2020-09-16

ISSN :

0902-4441

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hématologie

Résumé en anglais : [en]

Abstract Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the function of activated FVIII deficient in haemophilia A, represents a major therapeutic advance in the management of haemophilia ...
Lire la suite >Abstract Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the function of activated FVIII deficient in haemophilia A, represents a major therapeutic advance in the management of haemophilia A patients. No dosage adjustment is required, which leads to a major change for patients used to regular biological monitoring which is particularly burdensome in the case of substitution therapy. In some circumstances, such as before an invasive procedure or in case of bleeding, biological monitoring will be necessary and emicizumab's interference with haemostasis tests, particularly those based on an activated partial thromboplastin times (aPTT), must be known to best interpret the tests and to select the most appropriate methods to guide therapy. The normalisation of aPTT in patients treated with emicizumab is not sufficient to consider haemostasis as normalised. In the event of administration of FVIII to a patient receiving emicizumab, the determination of FVIII should use a chromogenic method using non‐human reagents. Coagulation global tests have been proposed to evaluate the biological response when using bypassing agents in patients treated with emicizumab, but the usefulness must be confirmed. The French group BIMHO presents proposals for biological monitoring of a patient treated with emicizumab according to clinical situations.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL